NCT04711252: A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease

Breast Cancer Type: HR+ & HER2-negative
Hormone Mutations: ER+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 3
Drug Category: Endocrine (Hormone Therapy, Serine-Threonine Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years to 130 Years (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Check trial for requirements on previous hormone therapy
Exclusions: Patients with previous treatment of an AI +/- a CDK4/6 inhibitor with disease recurrence while on or within 12 months of completing treatment; Patients previously treated with any systemic anti-cancer therapy; Patients with previous treatment of AZD9833; Patients with known active uncontrolled or symptomatic CNS metastases, carcinomatous meningitis, or leptomeningeal disease

Comments are closed.

Up ↑